Alphonse R. Ouedraogo

Ouagadougou, Burkina Faso

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 107 publications

IgG and IgM responses to PfEMP1 domains associated with semi-immunity to clinical malaria in Burkinabe children under five.

IgG and IgM responses to PfEMP1 domains associated with semi-immunity to clinical malaria in Burkinabe children under five.

Journal: Frontiers in immunology

Published: January 06, 2026

Impact of directly observed treatment and extended age range of seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in Burkina Faso: a three-group, open-label, cluster-randomised, controlled trial.

Impact of directly observed treatment and extended age range of seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in Burkina Faso: a three-group, open-label, cluster-randomised, controlled trial.

Journal: The Lancet. Infectious diseases

Published: December 22, 2025

Incidence and antimicrobial resistance of non-typhoidal Salmonella enterica in stool samples from children under five in peri-urban Ouagadougou, Burkina Faso.

Incidence and antimicrobial resistance of non-typhoidal Salmonella enterica in stool samples from children under five in peri-urban Ouagadougou, Burkina Faso.

Journal: BMC microbiology

Published: September 09, 2025

Five-Year Experience of the Groupe de Recherche Action en Santé (GRAS) Clinical Laboratory, Burkina Faso, in Participating into an External Proficiency Testing (EPT) Programme.

Five-Year Experience of the Groupe de Recherche Action en Santé (GRAS) Clinical Laboratory, Burkina Faso, in Participating into an External Proficiency Testing (EPT) Programme.

Journal: Diagnostics (Basel, Switzerland)

Published: August 27, 2025

Uncomplicated malaria as a risk factor for COVID-19 duration and severity in western Kenya and Burkina Faso (MALCOV): a prospective cohort study.

Uncomplicated malaria as a risk factor for COVID-19 duration and severity in western Kenya and Burkina Faso (MALCOV): a prospective cohort study.

Journal: The Lancet. Global health

Published: June 20, 2025

A Multiplex Serological Assay to Evaluate the Antibody Responses to a Set of Plasmodium falciparum Antigens and Their Protective Role Against Malaria in Children Aged 1.5 to 12 Years Living in a Highly Seasonal Malaria Transmission Area of Burkina Faso.

A Multiplex Serological Assay to Evaluate the Antibody Responses to a Set of Plasmodium falciparum Antigens and Their Protective Role Against Malaria in Children Aged 1.5 to 12 Years Living in a Highly Seasonal Malaria Transmission Area of Burkina Faso.

Journal: Vaccines

Published: June 17, 2025

Artemether-lumefantrine versus pyronaridine-artesunate for the treatment of malaria in patients with mild to moderate COVID-19 in Kenya and Burkina Faso: a randomised open-label trial (MALCOV).

Artemether-lumefantrine versus pyronaridine-artesunate for the treatment of malaria in patients with mild to moderate COVID-19 in Kenya and Burkina Faso: a randomised open-label trial (MALCOV).

Journal: EClinicalMedicine

Published: May 31, 2025

Application of a high-resolution melt assay for monitoring SARS-CoV-2 variants in Burkina Faso and Kenya.

Application of a high-resolution melt assay for monitoring SARS-CoV-2 variants in Burkina Faso and Kenya.

Journal: mSphere

Published: May 29, 2025

Burden of Shigella infection in children under five years living in a peri-urban area of Ouagadougou, Burkina Faso: A community-based cohort study.

Burden of Shigella infection in children under five years living in a peri-urban area of Ouagadougou, Burkina Faso: A community-based cohort study.

Journal: PLoS neglected tropical diseases

Published: May 13, 2025

Single low-dose primaquine for malaria control in Africa: a systematic review of safety, efficacy and implementation barriers.

Single low-dose primaquine for malaria control in Africa: a systematic review of safety, efficacy and implementation barriers.

Journal: BMJ global health

Published: April 23, 2025

Protective targets of PfSPZ vaccines identified from whole-genome sieve analysis of isolates from malaria vaccine efficacy trials in West Africa.

Protective targets of PfSPZ vaccines identified from whole-genome sieve analysis of isolates from malaria vaccine efficacy trials in West Africa.

Journal: medRxiv : the preprint server for health sciences

Published: March 17, 2025

Antibody responses in Burkinabe children against P. falciparum proteins associated with reduced risk of clinical malaria.

Antibody responses in Burkinabe children against P. falciparum proteins associated with reduced risk of clinical malaria.

Journal: Frontiers in immunology

Published: November 01, 2024

Showing 1-12 of 107

Last Updated: 09/26/2026